Efficacy of Pentosan Polysulfate Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome Efficacy of Pentosan Polysulfate Treatment
Main Article Content
Keywords
摘要
Objectives: Pentosan Polysulfate (PPS) is the only oral treatment for interstitial cystitis (IC)-bladder pain syndrome (BPS) approved by the World Health Organization. Self-evaluation scales can provide more objective results on pre- and post-treatment satisfaction. The aim of this study was to investigate the effect of pentosan polysulfate treatment on symptoms in IC-BPS patients.
Methods: This study included 37 adult male and female patients with IC-BPS who reported pain, urinary urgency, polyurea, and nocturia without urinary tract infection for a minimum of six months prior to the study and were taking 300 mg/day oral pentosan polysulfate. Pre- and post-treatment symptoms, Interstitial Cystitis Symptom Index (ICSI) Scores, quality of life (QoL) scores (1‒4), and satisfaction conditions were examined.
Results: Following the application of inclusion and exclusion criteria, mean age of 37 suitable patients was 46.0±11.9 years and 27% (10 individuals) of the patients were male. Pre-treatment, ICSI scores, and measures of satisfaction degree and QoL increased significantly after the treatment (p<0.001). Adverse reaction was detected in two patients (5.4%) among the patients treated with pentosan polysulfate.
Conclusions: Oral pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome treatment could achieve recovery in symptoms, increase Interstitial Cystitis Symptom Index score and improve quality of life and patient satisfaction.
##plugins.generic.paperbuzz.metrics##
参考
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. ; Standardisation Sub-Committee of the International Continence Society.The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003 Jan;61(1):3749. https://doi.org/10.1016/S0090-4295(02)02243-4 PMID:12559262
3. Sand PK, Kaufman DM, Evans RJ, Zhang HF, Alan Fisher DL, Nickel JC. Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction. Curr Med Res Opin. 2008;24(8):2259-64. Epub 20080625. https://doi.org/10.1185/03007990802240727.PMID: 18582395.
4. Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol. 2005 Dec;174(6):2231-4. https://doi.org/10.1097/01.ju.0000181203.82693.95 PMID:16280776
5. Marcu I, Campian EC, Tu FF. Interstitial Cystitis/Bladder Pain Syndrome. Semin Reprod Med. 2018;36(2):123-35. Epub 20181219.https://doi.org/10.1055/s-0038-1676089. . PMID: 30566978.
6. Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological A. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545-53. Epub 20150123. https://doi.org/10.1016/j.juro.2015.01.086 PMID: 25623737.
7. Nickel JC, Herschorn S, Whitmore KE, Forrest JB, Hu P, Friedman AJ, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857-62. Epub 20140920.https://doi.org/10.1016/j.juro.2014.09.036.. PMID: 25245489.
8. O'Leary MP, Sant GR, Fowler FJ, Jr., Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58-63. https://doi.org/10.1016/S0090-4295(99)80333-1.PMID: 9146003.
9. Arda E, Cakiroglu B, Tas T, Ekici S, Uyanik BS: Use of the UPOINT Classification in Turkish Chronic Prostatitis or Chronic Pelvic Pain Syndrome Patients. Urology. 2016, 97:227-23. https://doi.org/10.1016/j.urology.2016.07.023 PMID:27476153
10. Giusto LL, Zahner PM, Shoskes DA. An evaluation of the pharmacotherapy for interstitial cystitis. Expert Opin Pharmacother. 2018;19(10):1097-108. Epub 20180704. https://doi.org/10.1080/14656566.2018.1491968. PMID: 29972328.
11. Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35-48. Epub 20090831. https://doi.org/10.1016/j.eururo.2009.08.020.PMID: 19733958.
12. Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993 Sep;150(3):845-8. https://doi.org/10.1016/S0022-5347(17)35629-X PMID:7688432
13. van Ophoven A, Vonde K, Koch W, Auerbach G, Maag KP. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr Med Res Opin. 2019;35(9):1495-503. Epub 20190319. https://doi.org/10.1080/03007995.2019.1586401.PMID: 30849922.
14. Holm-Bentzen M, Jacobsen F, Nerstrøm B, Lose G, Kristensen JK, Pedersen RH, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol. 1987 Sep;138(3):503-7. https://doi.org/10.1016/S0022-5347(17)43241-1 PMID:2442415
15. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al ; Interstitial Cystitis Clinical Trials Group.. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep;170(3):810-5. https://doi.org/10.1097/01.ju.0000083020.06212.3d PMID:12913705
16. Hwang P, Auclair B, Beechinor D, Diment M, Einarson TR. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology. 1997 Jul;50(1):39-43. https://doi.org/10.1016/S0090-4295(97)00110-6 PMID:9218016
17. Wyndaele JJJ, Riedl C, Taneja R, Lovasz S, Ueda T, Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019;38(2):535-44. Epub 20181228. https://doi.org/10.1002/nau.23900.PMID: 30592544.
18. Fritjofsson A, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol. 1987 Sep;138(3):508-12. https://doi.org/10.1016/S0022-5347(17)43242-3 PMID:2442416
19. Clemens JQ, Calhoun EA, Litwin MS, McNaughton-Collins M, Kusek JW, Crowley EM, et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology. 2009;74(5):983-7, quiz 7 e1-3. Epub 20091002. dhttps://doi.org/10.1016/j.urology.2009.06.078. PMID: 19800663; PubMed Central PMCID: PMCPMC2783956.
20. van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005 Nov;174(5):1837-40. https://doi.org/10.1097/01.ju.0000176741.10094.e0 PMID:16217303
21. Guidelines EA 2022. Available from: https://uroweb.org/guidelines/chronic-pelvic-pain
22. Anderson VR, Perry CM. Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs. 2006;66(6):821-35. https://doi.org/10.2165/00003495-200666060-00006 PMID:16706553
23. Tseng CS, Chang SJ, Meng E, Chang HC, Lee YJ. The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial. J Formos Med Assoc. 2020;119(8):1314-9. Epub 20191205. https://doi.org/10.1016/j.jfma.2019.11.007. PMID: 31813658.
24. Wang D, Velaga SB, Grondin C, Au A, Nittala M, Chhablani J, et al. Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening. Am J Ophthalmol. 2021;227:125-38. Epub 20210227.https://doi.org/10.1016/j.ajo.2021.02.025. PMID: 33651989.